Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration

Ther Deliv. 2021 Mar;12(3):191-200. doi: 10.4155/tde-2020-0132. Epub 2021 Mar 1.

Abstract

Current treatment of neovascular age-related macular degeneration involves periodic intravitreal injections of anti-VEGF medication, creating a burden to patients and physicians, resulting in nonadherence to recommended dosing schedules. The Port Delivery System with ranibizumab offers a long-term solution that involves implantation of a device into the pars plana and provides continuous release of anti-VEGF medication into the vitreous, thus requiring fewer office visits. The Port Delivery System has demonstrated comparable visual and anatomic outcomes to monthly injections and shows promise in alleviating the patient burden in the treatment of neovascular age-related macular degeneration, making possible better long-term real-world visual outcomes.

Keywords: AMD; PDS; anti-VEGF; implant; ranibizumab.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Humans
  • Intravitreal Injections
  • Macular Degeneration* / drug therapy
  • Ranibizumab* / therapeutic use
  • Treatment Outcome
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Ranibizumab